Vaccines for Lung Cancer

  • Michael A. Morse
  • Jennifer Garst
  • Eric Toloza
Part of the Cancer Drug Discovery and Development book series (CDD&D)


The disappointing long-term survival for non-small-cell (NSCLC) and small-cell (SCLC) lung cancers has highlighted the need for additional strategies. The modest activity of therapies targetting epidermal growth factor receptor (EGFR) suggests that other targeted therapies such as immunotherapy are worthy of consideration. Several recent reviews have addressed this topic (1,2). Although renal cell carcinoma and melanoma are the classic targets for immunotherapy, attempts to activate the immune system against lung cancer have actually been ongoing for 30 yr or more. The initial approaches used bacterial cell wall products to cause a profound, but nonspecific, inflammatory response. Occasional studies demonstrated clinical benefit, and some of these agents are still being tested. Modern theories regarding the role of antigen-specific immune response, though, have given greater impetus to develop vaccines that activate immune responses against specific tumor antigens. This chapter will focus on the role of vaccines to activate immune responses against lung cancers.


Lung Cancer Epidermal Growth Factor Receptor Human Leukocyte Antigen Small Cell Lung Cancer Lung Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Swisher SG, Roth JA, Carbone DP. Genetic and immunologic therapies for lung cancer. Semin Oncol 2002; 29:95–101.PubMedCrossRefGoogle Scholar
  2. 2.
    Salgaller ML. The development of immunotherapies for non-small cell lung cancer. Expert Opin Biol Ther 2002; 2:265–278.PubMedCrossRefGoogle Scholar
  3. 3.
    Johnston-Early A, Cohen MH, Fossieck BE, Jr, et al. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer. Cancer 1983; 52:1395–1400.PubMedCrossRefGoogle Scholar
  4. 4.
    Fischer JR, Schindel M, Bulzebruck H, Lahm H, Krammer PH, Drivsholm L. Long-term survival in small cell lung cancer patients is correlated with high interleukin-2 secretion at diagnosis. J Cancer Res Clin Oncol 2000; 126:730–733.PubMedCrossRefGoogle Scholar
  5. 5.
    Nakamura H, Saji H, Ogata A, et al. Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 2002; 37:161–169.PubMedCrossRefGoogle Scholar
  6. 6.
    Foukas PG, Tsilivakos V, Zacharatos P, et al. Expression of HLA-DR is reduced in tumor infiltrating immune cells (TIICs) and regional lymph nodes of non-small-cell lung carcinomas. A putative mechanism of tumor-induced immunosuppression? Anticancer Res 2001; 21:2609–2615.PubMedGoogle Scholar
  7. 7.
    Takenoyama M, Yasumoto K, Harada M, et al. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer. Immunobiology 1996; 195:140–151.PubMedCrossRefGoogle Scholar
  8. 8.
    Takenoyama M, Yasumoto K, Harada M, Sugimachi K, Nomoto K. Antitumor response of regional lymph node lymphocytes in human lung cancer. Cancer Immunol Immunother 1998; 47:213–220.PubMedCrossRefGoogle Scholar
  9. 9.
    Winter SF, Sekido Y, Minna JD, et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Nail Cancer Inst 1993; 85:2012–2018.CrossRefGoogle Scholar
  10. 10.
    Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997; 15:2866–2872.PubMedGoogle Scholar
  11. 11.
    Blaes F. Immunotherapeutic approaches to paraneoplastic neurological disorders. Expert Opin Investig Drugs 2000; 9:727–733.PubMedCrossRefGoogle Scholar
  12. 12.
    Lai CL, Tsai CM, Tsai TT, et al. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res 1998; 4:3025–3030.PubMedGoogle Scholar
  13. 13.
    Laudanski J, Burzykowski T, Niklinska W, Chyczewski K, Furman M, Niklinski J. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Lung Cancer 1998; 22:191–200.PubMedCrossRefGoogle Scholar
  14. 14.
    Mitsudomi T, Suzuki S, Yatabe Y, et al. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J Natl Cancer Inst 1998; 90:1563–1568.PubMedCrossRefGoogle Scholar
  15. 15.
    Mack U, Ukena D, Montenarh M, Sybrecht GW. Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 2000; 7:669–674.PubMedGoogle Scholar
  16. 16.
    Zalcman G, Tredaniel J, Schlichtholz B, et al. Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. Int J Cancer 2000; 89:81–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Rosenfeld MR, Malats N, Schramm L, et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst 1997; 89:381–385.PubMedCrossRefGoogle Scholar
  18. 18.
    Jassem E, Bigda J, Dziadziuszko R, et al. Serum p53 antibodies in small cell lung cancer: the lack of prognostic relevance. Lung Cancer 2001; 31:17–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Bergqvist MBD, Larsson A, Holmertz J, et al. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. Anticancer Res 1998; 18:1999–2002.PubMedGoogle Scholar
  20. 20.
    Murray PV, Soussi T, O’Brien ME, et al. Serum p53 antibodies: predictors of survival in small-cell lung cancer? Br J Cancer 2000; 83:1418–1424.PubMedCrossRefGoogle Scholar
  21. 21.
    Takenoyama M, Yoshino I, Eifuku R, et al. Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells. Jpn J Cancer Res 2001; 92:309–315.PubMedCrossRefGoogle Scholar
  22. 22.
    Echchakir H, Asselin-Paturel C, Dorothee G, et al. Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas. Int J Cancer 1999; 81:205–213.PubMedCrossRefGoogle Scholar
  23. 23.
    Weynants P, Thonnard J, Marchand M, Delos M, Boon T, Coulie PG. Derivation of tumor-specific cytolytic T-cell clones from two lung cancer patients with long survival. Am J Respir Crit Care Med 1999; 159:55–62.PubMedGoogle Scholar
  24. 24.
    Yoshino I, Goedegebuure PS, Peoples GE, et al. HER2/neu-derived peptides are shared antigens among human non-small-cell lung cancer and ovarian cancer. Cancer Res 1994; 54:3387–3398.PubMedGoogle Scholar
  25. 25.
    Yoshino I, Takenoyama M, Fujie H, et al. The induction of cytotoxic T lymphocytes against HLA-A locus-matched lung adenocarcinoma in patients with non-small cell lung cancer. Jpn J Cancer Res 1997; 88:743–749.PubMedCrossRefGoogle Scholar
  26. 26.
    Semino C, Cilli M, Ratto GB, et al. Limiting dilution analysis of peripheral blood lymphocytes reacting with non-small-cell lung cancer: functionally heterogeneous effectors efficiently lyse autologous cancer cells. Lung Cancer 1998; 21:27–36.PubMedCrossRefGoogle Scholar
  27. 27.
    Makita M, Hiraki A, Azuma T, et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002; 8:2626–2631.PubMedGoogle Scholar
  28. 28.
    Shichijo S, Hayashi A, Takamori S, et al. Detection of MAGE-4 protein in lung cancers. Int J Cancer 1995; 64:158–165.PubMedCrossRefGoogle Scholar
  29. 29.
    Gotoh K, Yatabe Y, Sugiura T, et al. Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer 1998; 20:117–125.PubMedCrossRefGoogle Scholar
  30. 30.
    Yoshimatsu T, Yoshino I, Ohgami A, et al. Expression of the melanoma antigen-encoding gene in human lung cancer. J Surg Oncol Suppl 1998; 67:126–129.CrossRefGoogle Scholar
  31. 31.
    Scanlan MJ, Altorki NK, Gure AO, et al. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 2000; 150:155–164.PubMedCrossRefGoogle Scholar
  32. 32.
    Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, et al. Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002; 236: 785–793PubMedCrossRefGoogle Scholar
  33. 33.
    Sugita M, Geraci M, Gao B, et al. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res 2002; 62:3971–3979.PubMedGoogle Scholar
  34. 34.
    Eifuku R, Takenoyama M, Yoshino I, et al. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes. Int J Clin Oncol 2001; 6:34–39.PubMedCrossRefGoogle Scholar
  35. 35.
    Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001; 92:856–860.PubMedCrossRefGoogle Scholar
  36. 36.
    Gnjatic S, Altorki NK, Stockert E, et al. NY-ESO-1 peptide immunization of patients with non-small cell lung cancer expressing NY-ES0–1 antigen. Proc Am Soc Clin Oncol 2002; 21:29b (abstr 1926).Google Scholar
  37. 37.
    Menssen HD, Bertelmann E, Bartelt S, et al. Wilms’ tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J Cancer Res Clin Oncol 2000; 126:226–232.PubMedCrossRefGoogle Scholar
  38. 38.
    Wroblewski JM, Bixby DL, Borowski C, Yannelli JR. Characterization of human non-small cell lung cancer (NSCLC) cell lines for expression of MHC, co-stimulatory molecules and tumor-associated antigens. Lung Cancer 2001; 33:1811–1894.CrossRefGoogle Scholar
  39. 39.
    Bauer CDI, Brass N, Steinhart H, Iro H, Meese EU. Translation initiation factor eIF-4G is immunogenic, overexpressed, and amplified in patients with squamous cell lung carcinoma. Cancer 2001; 92:822–829.PubMedCrossRefGoogle Scholar
  40. 40.
    Ozaki Y, Kontani K, Hanaoka J, Chano T, Teramoto K, Tezuka N, et al. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer 2002; 95: 1954–1962.PubMedCrossRefGoogle Scholar
  41. 41.
    Cox G, Vyberg M, Melgaard B, Askaa J, Oster A, O’Byrne KJ. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 2001; 92:480–483.PubMedCrossRefGoogle Scholar
  42. 42.
    Hirsch FR, Varella-Garcia M, Franklin WA, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002; 86:1449–1456.PubMedCrossRefGoogle Scholar
  43. 43.
    Selvaggi G, Scagliotti GV, Toni V, et al. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. Cancer 2002; 94:2669–2674.PubMedCrossRefGoogle Scholar
  44. 44.
    Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515–522.PubMedGoogle Scholar
  45. 45.
    Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA, Jr. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 2002; 29:3–14.PubMedCrossRefGoogle Scholar
  46. 46.
    Hanaoka J, Kontani K, Sawai S, et al. Analysis of MUC4 mucin expression in lung carcinoma cells and its immunogenicity. Cancer 2001; 92:2148–2157.PubMedCrossRefGoogle Scholar
  47. 47.
    Seregni E, Botti C, Lombardo C, Cantoni A, Bogni A, Cataldo I, Bombardieri E. Pattern of mucin gene expression in normal and neoplastic lung tissues. Anticancer Res 1996; 16(4B):2209–2213.PubMedGoogle Scholar
  48. 48.
    Lowe J, Iles PB, Shore DF, et al. Intrapleural BCG in operable lung cancer. Lancet 1980; 1:11.PubMedCrossRefGoogle Scholar
  49. 49.
    Gail MH. A placebo-controlled randomized double-blind study of adjuvant intrapleural BCG in patients with resected T1 NO, T1N1, or T2NO squamous cell carcinoma, adenocarcinoma, or large cell carcinoma of the lung. LCSG Protocol 771. Chest 1994; 106:2875–292S.CrossRefGoogle Scholar
  50. 50.
    Sakamoto J, Teramukai S, Watanabe Y, et al. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer. J Immunother 2001; 24:250–256.CrossRefGoogle Scholar
  51. 51.
    Assersohn L, Souberbielle BE, O’Brien ME, Archer CD, Mendes R, Bass R, et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin Oncol (R Coll Radiol) 2002; 14(1):23–27.CrossRefGoogle Scholar
  52. 52.
    O’Brien ME, Saini A, Smith JE, et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000; 83:853–857.PubMedCrossRefGoogle Scholar
  53. 53.
    Iwakami SI, Setoguchi Y, Saijo Y, Azuma M, Fukuchi Y. Replication-deficient adenovirus-mediated transfer of B7–1 (CD80) cDNA induces anti-tumour immunity in isolated human lung cancer. Respirology 2001; 6:135–144.PubMedCrossRefGoogle Scholar
  54. 54.
    Raez LE, Cassileth P, Sridar K, et al. Novel vaccination in patients with non-small cell lung cancer (NSCLC) using an allogeneic adenocarcinoma (AD100-B7.1(CD80)/HLA) vaccine. Proc Am Soc Clin Oncol 2002; 21:3b (abstr 1821).Google Scholar
  55. 55.
    Nemunaitis J, Sterman D, Jablons D, et al. A phase I/II trial of autologous GM-CSF gene modified cancer vaccines in subjects with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:255a (abstr 1019).Google Scholar
  56. 56.
    Nemunaitis JJ, Smith J, Sterman D, et al. A phase I/II trial of bystander GVAX cancer vaccine in nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21:13a (abstr 1948).Google Scholar
  57. 57.
    Takita H, Hollinshead AC, Adler RH, et al. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5-year survival analysis. J Surg Oncol Suppl 1991; 46:9–14.CrossRefGoogle Scholar
  58. 58.
    Morse MA. Technology evaluation: BLP-25, Biomira, Inc. Curr Opin Mol Ther 2001; 3(1):102–105.PubMedGoogle Scholar
  59. 59.
    Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235:540–549.PubMedCrossRefGoogle Scholar
  60. 60.
    Itoh T, Ueda Y, Kawashima I, et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 2002; 51: 99–106.PubMedCrossRefGoogle Scholar
  61. 61.
    Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with F1t3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001; 98:8809–8814.PubMedCrossRefGoogle Scholar
  62. 62.
    Morse MA, Garst J, Khan S, et al. Preliminary results of a phase I/II study of active immunotherapy with autologous dexosomes loaded with MAGE peptides in HLA A2+ patients with stage III/IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2002; 21:11a (abstr 42).Google Scholar
  63. 63.
    Grant SC, Kris MG, Houghton AN, Chapman PB. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus bacillus Calmette-Guérin. Clin Cancer Res 1999; 5:1319–1323.PubMedGoogle Scholar
  64. 64.
    Shepherd FA. Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer. Semin Oncol 2001; 28:30–37.PubMedCrossRefGoogle Scholar
  65. 65.
    Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57:1007–1012.PubMedGoogle Scholar
  66. 66.
    Oizumi S, Yamazaki K, Nakashima M, et al. RCAS1 expression: a potential prognostic marker for adenocarcinomas of the lung. Oncology 2002; 62:333–339.PubMedCrossRefGoogle Scholar
  67. 67.
    Katsenelson NS, Shurin GV, Bykovskaia SN, Shogan J, Shurin MR. Human small cell lung carcinoma and carcinoid tumor regulate dendritic cell maturation and function. Mod Pathol 2001; 14:40–45.PubMedCrossRefGoogle Scholar
  68. 68.
    Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 1998; 113:173–182.PubMedCrossRefGoogle Scholar
  69. 69.
    Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168:4272–4276.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Michael A. Morse
  • Jennifer Garst
  • Eric Toloza

There are no affiliations available

Personalised recommendations